IL226706A - Sigma ligands for use in bone cancer pain - Google Patents

Sigma ligands for use in bone cancer pain

Info

Publication number
IL226706A
IL226706A IL226706A IL22670613A IL226706A IL 226706 A IL226706 A IL 226706A IL 226706 A IL226706 A IL 226706A IL 22670613 A IL22670613 A IL 22670613A IL 226706 A IL226706 A IL 226706A
Authority
IL
Israel
Prior art keywords
bone cancer
cancer pain
sigma ligands
ligands
sigma
Prior art date
Application number
IL226706A
Other languages
English (en)
Hebrew (he)
Inventor
Jose Miguel Vela Hernandez
Daniel Zamanillo-Castanedo
Carlos Platasalaman
Original Assignee
Esteve Labor Dr
Jose Miguel Vela Hernandez
Daniel Zamanillo-Castanedo
Carlos Platasalaman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr, Jose Miguel Vela Hernandez, Daniel Zamanillo-Castanedo, Carlos Platasalaman filed Critical Esteve Labor Dr
Publication of IL226706A publication Critical patent/IL226706A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • C07D231/20One oxygen atom attached in position 3 or 5
    • C07D231/22One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41521,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL226706A 2010-12-03 2013-06-03 Sigma ligands for use in bone cancer pain IL226706A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382330A EP2460519A1 (en) 2010-12-03 2010-12-03 Use of sigma ligands in bone cancer pain
PCT/EP2011/071584 WO2012072782A1 (en) 2010-12-03 2011-12-02 Use of sigma ligands in bone cancer pain

Publications (1)

Publication Number Publication Date
IL226706A true IL226706A (en) 2015-07-30

Family

ID=43629676

Family Applications (1)

Application Number Title Priority Date Filing Date
IL226706A IL226706A (en) 2010-12-03 2013-06-03 Sigma ligands for use in bone cancer pain

Country Status (35)

Country Link
US (1) US20130324535A1 (enExample)
EP (2) EP2460519A1 (enExample)
JP (1) JP6027014B2 (enExample)
KR (1) KR101855358B1 (enExample)
CN (1) CN103313709B (enExample)
AR (1) AR084730A1 (enExample)
BR (1) BR112013013369A8 (enExample)
CA (1) CA2819442C (enExample)
CO (1) CO6781549A2 (enExample)
CY (1) CY1119030T1 (enExample)
DK (1) DK2646025T3 (enExample)
ES (1) ES2626672T3 (enExample)
HR (1) HRP20170818T1 (enExample)
HU (1) HUE033488T2 (enExample)
IL (1) IL226706A (enExample)
LT (1) LT2646025T (enExample)
MA (1) MA34878B1 (enExample)
ME (1) ME02852B (enExample)
MX (1) MX343773B (enExample)
MY (1) MY171994A (enExample)
NZ (1) NZ612119A (enExample)
PH (1) PH12013501127A1 (enExample)
PL (1) PL2646025T3 (enExample)
PT (1) PT2646025T (enExample)
RS (1) RS56081B1 (enExample)
RU (1) RU2585095C2 (enExample)
SG (1) SG190745A1 (enExample)
SI (1) SI2646025T1 (enExample)
SM (1) SMT201700270T1 (enExample)
TN (1) TN2013000227A1 (enExample)
TR (1) TR201708567T4 (enExample)
TW (1) TWI629060B (enExample)
UA (1) UA112638C2 (enExample)
WO (1) WO2012072782A1 (enExample)
ZA (1) ZA201304966B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2426111A1 (en) * 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2792352A1 (en) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
EP2818166A1 (en) * 2013-06-26 2014-12-31 Laboratorios del Dr. Esteve S.A. Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)
AR100021A1 (es) * 2013-09-12 2016-09-07 Esteve Labor Dr Combinaciones de ligando de receptores sigma y aine
AU2014364647A1 (en) 2013-12-17 2016-06-23 Laboratorios Del Dr. Esteve, S.A. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Sigma receptor ligands combinations
AU2014364644A1 (en) 2013-12-17 2016-06-23 Laboratorios Del Dr. Esteve, S.A. Gabapentinoids and Sigma receptor ligands combinations
EP2929883A1 (en) * 2014-04-08 2015-10-14 Institut Pasteur Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors
AR109024A1 (es) * 2016-07-12 2018-10-17 Esteve Labor Dr Uso de ligandos del receptor sigma en el dolor post-herpético
EP3415143A1 (en) * 2017-06-16 2018-12-19 Kai-Uwe Kern Bromhexine for the treatment of pain
WO2019224184A1 (en) * 2018-05-21 2019-11-28 Ipsen Biopharm Limited Suppression of bone cancer-induced allodynia
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN112341397B (zh) * 2019-08-09 2023-05-23 成都苑东生物制药股份有限公司 吡嗪类衍生物或盐、异构体、其制备方法及用途
KR102744822B1 (ko) 2020-06-05 2024-12-20 주식회사 허밍아비스 발열체 조성물 및 이를 이용한 마스크 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1832928B (zh) * 2003-06-26 2012-07-04 诺瓦提斯公司 以5元杂环为基础的p38激酶抑制剂
EP2325174A1 (en) 2004-08-27 2011-05-25 Laboratorios Del. Dr. Esteve, S.A. Sigma receptor inhibitors
RU2417987C2 (ru) * 2004-08-27 2011-05-10 Лабораторьос Дель Др.Эстеве, С.А. Ингибиторы сигма-рецептора
US8202872B2 (en) * 2006-03-01 2012-06-19 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
EP2113501A1 (en) * 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
EP2116539A1 (en) * 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof

Also Published As

Publication number Publication date
MA34878B1 (fr) 2014-02-01
MY171994A (en) 2019-11-11
SMT201700270T1 (it) 2017-07-18
HUE033488T2 (en) 2017-12-28
EP2646025B1 (en) 2017-03-15
ES2626672T3 (es) 2017-07-25
SI2646025T1 (sl) 2017-07-31
TW201249805A (en) 2012-12-16
EP2460519A1 (en) 2012-06-06
SG190745A1 (en) 2013-07-31
PL2646025T3 (pl) 2017-09-29
AR084730A1 (es) 2013-06-05
BR112013013369A8 (pt) 2018-01-09
CO6781549A2 (es) 2013-10-31
LT2646025T (lt) 2017-06-12
PH12013501127A1 (en) 2020-10-19
AU2011334880B2 (en) 2016-09-15
ME02852B (me) 2018-04-20
CY1119030T1 (el) 2018-01-10
CN103313709A (zh) 2013-09-18
EP2646025A1 (en) 2013-10-09
TN2013000227A1 (en) 2014-11-10
WO2012072782A1 (en) 2012-06-07
HRP20170818T1 (hr) 2017-08-25
CA2819442A1 (en) 2012-06-07
ZA201304966B (en) 2014-09-25
NZ612119A (en) 2014-06-27
MX2013006140A (es) 2013-07-03
UA112638C2 (uk) 2016-10-10
RU2013130222A (ru) 2015-01-10
US20130324535A1 (en) 2013-12-05
TR201708567T4 (tr) 2019-01-21
JP2014501732A (ja) 2014-01-23
KR20130135881A (ko) 2013-12-11
BR112013013369A2 (pt) 2016-09-06
PT2646025T (pt) 2017-06-26
DK2646025T3 (en) 2017-06-06
KR101855358B1 (ko) 2018-05-04
TWI629060B (zh) 2018-07-11
CA2819442C (en) 2018-06-12
RS56081B1 (sr) 2017-10-31
AU2011334880A1 (en) 2013-07-11
RU2585095C2 (ru) 2016-05-27
MX343773B (es) 2016-11-23
CN103313709B (zh) 2017-05-24
JP6027014B2 (ja) 2016-11-16

Similar Documents

Publication Publication Date Title
IL226706A (en) Sigma ligands for use in bone cancer pain
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
ZA201303605B (en) Compounds and methods for treating pain
GB201308746D0 (en) Patient Specific Implants
ZA201208413B (en) Skin treatment composition
EP2543336A4 (en) ARTICULATOR
SI2780332T1 (sl) Morfolinilbenzotriazini za uporabo pri terapiji raka
IL222958A0 (en) Cancer treatment
ZA201301458B (en) Therapeutic agent for pain
IL238453A0 (en) Trans-clomiphene for use in cancer treatment
GB201011411D0 (en) Therapeutic compounds and their use
ZA201209452B (en) Gold complexes for use in the treatment of cancer
EP2593111A4 (en) NEW COMPOUNDS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
ZA201208568B (en) Skin treatment composition
EP2585115A4 (en) CANCER THERAPY
LT2872176T (lt) Karboranilporfirinai, skirti naudoti vėžio gydymui
GB0901465D0 (en) Compounds for use in therapy
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
PT2566579E (pt) Dispositivo médico para magnetoterapia
GB201120705D0 (en) Pain relief
GB201301168D0 (en) Cancer treatment
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer
GB201019034D0 (en) Treatment for tumors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed